Life Origin Biotechnology

Life Origin Biotechnology is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of mRNA-based therapeutics and vaccines. Founded in 2021, the company utilizes a proprietary mRNA synthesis platform and advanced Lipid Nanoparticle (LNP) delivery systems to target infectious diseases and oncology. Its lead program, LOB-01, is an mRNA vaccine candidate for COVID-19 that has entered clinical trials, while its early-stage pipeline includes vaccines for respiratory syncytial virus (RSV) and personalized cancer immunotherapies. Life Origin focuses on optimizing mRNA stability and delivery efficiency to provide next-generation preventative and therapeutic solutions. The company is backed by notable venture capital firms and aims to expand the utility of mRNA technology across various disease areas.